Will the FDA approve GSK’s hepatitis B treatment in the review targeting October 26?

Question

This market resolves YES if the US Food and Drug Administration approves bepirovirsen for treating chronic hepatitis B in adults as the first substantive decision on GSK's currently accepted application, whose announced target action date is October 26, 2026. Approval for a narrower adult hepatitis B population than originally requested still qualifies. The drug may receive a brand name, but the approved active treatment must be bepirovirsen, not another GSK medicine.

Both regular and accelerat

Problyx · Accepted Answer

Yes — the community forecast puts this at 81%.

Problyx · Answer

No — the community forecast puts this at 19%.